For the individual patient, further intervention is considered by comparing expected
outcomes with and without the intervention. Most experience with advanced heart failure has …

The epidemic of heart failure has been widely reported. 1–3 The reasons for its significant
increase in incidence are multiple and include improved survival with current drug therapy …

1552 months, 2, 16 indicating that when patients reach this stage of HF, there are very few
effective treatment options. This is especially true for those 65 years of age, when the …

Left ventricular assist devices are becoming an increasingly prevalent therapy for patients
with Stage D heart failure with reduced ejection fraction. Technological advances have …

Improvements in device technology as well as patient selection and management have led
to improved medium term (2–4 years) survival after VAD implant in nontransplant eligible …

OBJECTIVE: The REMATCH trial compared the use of left ventricular assist devices with
optimal medical management for patients with end-stage heart failure. When the trial met its …

Background: The paucity of available hearts for transplantation means that more patients
remain on durable left ventricular support for longer periods of time. The Registry to Evaluate …

DeBakey [1] achieved the first postcardiotomy mechanical bridge to recovery with a pulsatile
left ventricular assist device (LVAD) in 1966 (Fig. 1). The following year, Barnard [2] …

Background Implantable left ventricular assist devices have benefited patients with end-
stage heart failure as a bridge to cardiac transplantation, but their long-term use for the …

We describe our clinical experience with 205 implantable left ventricular assist devices at
the Cleveland Clinic between December 1991 and January 2000, along with manufacturers' …